Riskpilot← Back to searchSign inGet full accessAmaleigh AB
ABActiveOrg 5568383029Flohemsvägen 169Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20112 employees
Revenue 2025
SEK 485
EBITDA margin
-1736.1%
-5% vs 2024
Equity ratio
3.4%
Financial strength
Net profit 2025
SEK 5K
2 employees
| Revenue | SEK 485 | — |
| EBITDA | SEK -8K | -5% |
| Net profit | SEK 5K | — |
| Total assets | SEK 1,7M | -1% |
| Equity | SEK 58K | +8% |
| Employees | 2 | — |
Legal name
Amaleigh AB
Org number
5568383029
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 januari 2011
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att utföra konsulttjänster inom marknadsföring och koncernutveckling. Marknadsföring, försäljning av varor, distribution och servicetjänster inom medicinskteknologi. Importering och exportering av medicinsk- teknologiska varor samt underhåll av dessa varor. Medicinsk- teknologisk produktutveckling, investering och förvaltning av fastigheter inom Europa, investering i- och förvaltning av dotterbolag samt därmed förenlig verksamhet.
Address
Flohemsvägen 169
Email
mike.dooley@amaleigh.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 548 | 657 | 453 | 120 | 1 | 2 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −256 | 396 | −174 | 242 | 14 | −10 | −85 | −15 | −8 | −8 |
| Depreciation & amort. | −14 | −10 | −7 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| EBIT | −270 | 386 | −181 | 242 | 14 | −10 | −85 | −15 | −8 | −8 |
| Net financials | 24 | −319 | 68 | −174 | −41 | −41 | 86 | −15 | 7 | 13 |
| Profit before tax | −163 | 67 | −112 | 69 | −26 | −50 | 2 | −10 | 0 | 5 |
| Tax | −0 | −0 | −46 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| Net profit | −163 | 67 | −158 | 69 | −26 | −50 | 2 | −10 | 0 | 5 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2 144 | 2 205 | 2 448 | 1 877 | 1 896 | 1 911 | 1 798 | 1 718 | 1 709 | 1 693 |
| Equity | 61 | 128 | 70 | 139 | 113 | 62 | 64 | 54 | 54 | 58 |
| Long-term debt | 1 218 | 1 418 | 1 418 | 1 418 | 1 418 | 1 418 | 1 418 | 1 418 | 1 418 | 1 418 |
| Short-term debt | 865 | 659 | 960 | 320 | 365 | 431 | 316 | 246 | 238 | 217 |
| Total debt | 2 083 | 2 077 | 2 378 | 1 738 | 1 783 | 1 849 | 1 734 | 1 664 | 1 656 | 1 635 |
EBITDA margin
-1736.1%
This company
15.8%
Market median
-11088% vs market
20162025
Equity ratio
3.4%
This company
38.2%
Market median
-91% vs market
20162025
Return on equity
8.1%
This company
18.4%
Market median
-56% vs market
20162025
Net profit margin
971.3%
This company
8.1%
Market median
+11891% vs market
20162025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162025
Debt / equity
28.06×
This company
0.62×
Market median
-4426% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ML Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Amaleigh AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Leigh Dooley | Chief Executive Officer | 0 companies |
| Lynn Ware | Chairman | 0 companies |
| Ellinor Julia Autumn Dooley | Deputy Board Member | 0 companies |